Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30111818 | 0.98 | HTR2C (0.36) | HTR2CHTR2BSLC6A4PIM1PIM3 | |
| Hydrochloric Acid SCHEMBL28906178 | 0.98 | HTR2C (0.36) | HTR2CHTR2BSLC6A4PIM1PIM3 | |
| SCHEMBL25301249 | 0.81 | LOXL2 (0.35) | PIM1PIM3PIM2IDH1 | |
| SCHEMBL21810806 | 0.77 | HTR2C (0.50) | HTR2CHTR2BSLC6A4HTR2ASLC6A2 | |
| Hydrochloric Acid SCHEMBL21810793 | 0.76 | HTR2C (0.49) | HTR2CHTR2BSLC6A4HTR2ASLC6A2 | |
| SCHEMBL29277464 | 0.75 | LOXL2 (0.31) | — | |
| SCHEMBL31656597 | 0.75 | DYRK1A (0.35) | SLC6A4PIM1PIM3PIM2DYRK1A | |
| SCHEMBL31532572 | 0.72 | SLC6A4 (0.38) | HTR2CHTR2BSLC6A4HTR2ASLC6A2 | |
| SCHEMBL31308012 | 0.71 | LOXL2 (0.39) | IDH1 | |
| SCHEMBL30111755 | 0.70 | ACACB (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2021228795-A1 | NEW TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | F. HOFFMANN-LA ROCHE AG (CH) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRA3, GABRB3 | HTR2C 499/4885HTR2B 660/4885SLC6A4 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.